Skip to main content
SpringerLink
Log in

Treatment of Overactive Bladder in the Elderly Female: The Case for Trospium, Oxybutynin, Fesoterodine and Darifenacin

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Overactive bladder (OAB) is a common constellation of lower urinary tract storage symptoms that causes a significant impact on a person’s quality of life. The elderly may be disproportionally impacted by these symptoms due to concomitant poor mobility, comorbid conditions such as diabetes and heart failure, and polypharmacy. While behavioral modification and pelvic floor muscle training should be considered first-line treatment options, pharmacotherapy remains the backbone of the therapeutic regimen. Trospium, oxybutynin, fesoterodine, and darifenacin all have unique properties that may confer certain advantages in the elderly population. The hydrophilicity and quaternary amine structure of trospium may limit its ability to cross the blood–brain barrier and thus minimize impact on cognition in the elderly. In its oral form, oxybutynin may have the most significant effect on cognition; however, the transdermal preparations may be favorable in the elderly population due to the ability to avoid first-pass metabolism and its limited antimuscarinic adverse effects. Fesoterodine may be the most extensively studied OAB medication in the elderly population. Darifenacin has a strong affinity for the M3 receptor in the bladder, while having a weak affinity for the M1 receptor commonly found in the brain. It must be noted that all muscarinic receptor antagonists are associated with common adverse effects to some degree, and frequent re-evaluation of the elderly patient is necessary to confirm the proper benefit-to-risk profile.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Abrams P, Andersson KE, Birder L, Members of Committees; Fourth International Consultation on Incontinence, et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2010;29:213–40.

    Article  CAS  PubMed  Google Scholar 

  2. Stewart WF, van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327–36.

    CAS  PubMed  Google Scholar 

  3. Werner CA. The older population: 2010 (2010 Census Briefs). United States Census Bureau, United States Government Printing Office, Washington, DC, USA. 2011. http://www.census.gov/prod/cen2010/briefs/c2010br-09.pdf.

  4. Ganz ML, Smalarz AM, Krupski TL, et al. Economic costs of overactive bladder in the United States. Urology. 2010;75:526–32.

    Article  PubMed  Google Scholar 

  5. Coyne KS, Wein A, Nicholson S, et al. Economic burden of urgency urinary incontinence in the United States: a systematic review. JMCP. 2014;20:130–40.

    PubMed  Google Scholar 

  6. Rodriguez LV, Blander DS, Dorey F, et al. Discrepancy in patient and physician perception of patient’s quality of life related to urinary symptoms. Urology. 2003;62:49–53.

    Article  PubMed  Google Scholar 

  7. Koyne KS, Sexton CC, Irwin DE, et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008;101:1388–95.

    Article  Google Scholar 

  8. Sexton CC, Coyne KS, Vats V, et al. Impact of overactive bladder on work productivity in the United States: results from EpiLUTS. Am J Manag Care. 2009;15(4 Suppl):S98–107.

    PubMed  Google Scholar 

  9. Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care. 2000;6(11 Suppl):S574–9.

    CAS  PubMed  Google Scholar 

  10. de Groat WC, Theobald RJ. Reflex activation of sympathetic pathways to vesical smooth muscle and parasympathetic ganglia by electrical stimulation of vesical afferents. J Physiol. 1976;259:223–37.

    Article  PubMed Central  PubMed  Google Scholar 

  11. Ouslander JG. Management of overactive bladder. NEJM. 2004;350:786–99.

    Article  CAS  PubMed  Google Scholar 

  12. Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 2004;3:46–53.

    Article  CAS  PubMed  Google Scholar 

  13. Andersson K-E. Antimuscarinic mechanisms and the overactive detrusor: an update. Eur Urol. 2011;59:377–86.

    Article  CAS  PubMed  Google Scholar 

  14. Hawthorn MH, Chapple CR, Cock M, Chess-Williams R. Urothelium-derived inhibitory factor(s) influence detrusor muscle contractility in vitro. Br J Pharmacol. 2000;129:416–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Finney SM, Andersson KE, Gillespie JI, Stewart LH. Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int. 2006;98(3):503–7.

    Article  CAS  PubMed  Google Scholar 

  16. Mansfield KJ, Liu L, Mitchelson FJ, et al. Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes with ageing. Br J Pharmacol. 2005;144:1089–99.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Bschleipfer T, Schukowski K, Weidner W, et al. Expression and distribution of cholinergic receptors in the human urothelium. Life Sci. 2007;80:2303–7.

    Article  CAS  PubMed  Google Scholar 

  18. Abrams P, Andersson KE, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body systems and the implications for treating overactive bladder. Br J Pharmacol. 2006;148:565–78.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Zinner N, Tuttle J, Marks L. Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. World J Urol. 2005;23:248–52.

    Article  CAS  PubMed  Google Scholar 

  20. Chancellor MB, Staskin DR, Kay GG, Sandage BW Jr, Oefelein MG, Tsao JW. Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder. Drugs Aging. 2012;29:259–73.

    Article  CAS  PubMed  Google Scholar 

  21. Geyer J, Gavrilova O, Petzinger E. The role of P-glycoprotein in limiting brain penetration of the peripherally acting anticholinergic overactive bladder drug trospium chloride. Drug Metab Dispos. 2009;37:1371–4.

    Article  CAS  PubMed  Google Scholar 

  22. Geyer J, Gavrilova O, Schwantes U. Differences in the brain penetration of the anticholinergic drugs trospium chloride and oxybutynin. UroToday Int J. 2010;3:1.

    Article  Google Scholar 

  23. Callegari E, Malhotra B, Bungay PJ, et al. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. Br J Clin Pharmacol. 2011;72:235–46.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Elbadawi A, Yalla SV, Resnick NM. Structural basis of geriatric voiding dysfunction. III. Detrusor overactivity. J Urol. 1993;150:1668–80.

    CAS  PubMed  Google Scholar 

  25. Lowalekar SK, Cristofaro V, Radisavljevic ZM, et al. Loss of bladder smooth muscle caveolae in the aging bladder. Neurourol Urodyn. 2012;31:586–92.

    Article  PubMed  Google Scholar 

  26. Smith PP. Aging and the underactive detrusor: a failure of activity or activation? Neurourol Urodyn 2010;29:408–12.

  27. Staskin DR. Overactive bladder in the elderly: a guide to pharmacological management. Drugs Aging. 2005;22:1013–28.

    Article  CAS  PubMed  Google Scholar 

  28. Wagg AS, Cardozo L, Chapple C, et al. Overactive bladder syndrome in older people. BJU Int. 2007;99:502–9.

    Article  PubMed  Google Scholar 

  29. Kok ALM, Voorhorst FJ, Burger CW, et al. Urinary and faecal incontinence in community-residing older women. Age Ageing. 1992;21:211–5.

    Article  CAS  PubMed  Google Scholar 

  30. DuBeau EC. The aging urinary tract. J Urol. 2006;175:S11–5.

    Article  PubMed  Google Scholar 

  31. DuBeau EC. Beyond the bladder: management of urinary incontinence in older women. Clin Obstet Gynecol. 2007;50:720–34.

    Article  PubMed  Google Scholar 

  32. Gomelsky A, Dmochowski RR. Urinary incontinence in the aging female: etiology, pathophysiology and treatment options. Aging Health. 2011;7:79–88.

    Article  Google Scholar 

  33. Bentue-Ferrer D, Tribut O, Polard E, Allain H. Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists. CNS Drugs. 2003;17:947–63.

    Article  CAS  PubMed  Google Scholar 

  34. Carnahan RM, Lund BC, Perry PJ, et al. The concurrent use of anticholinergics and cholinesterase inhibitors: Rare event or common practice? J Am Geriatr Soc. 2004;52:2082–7.

    Article  PubMed  Google Scholar 

  35. Sink KM, Thomas J III, Xu H, Craig B, Kritchevsky S, Sands LP. Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes. J Am Geriatr Soc. 2008;56:847–53.

    Article  PubMed  Google Scholar 

  36. Agar M, Currow D, Plummer J, Seidel R, Carnahan R, Abernethy AP. Changes in anticholinergic load from regular prescribed medications in palliative care as death approaches. Palliat Med. 2009;23:257–65.

    Article  CAS  PubMed  Google Scholar 

  37. Tune LE. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry. 2001;62(Suppl 21):11–4.

    CAS  PubMed  Google Scholar 

  38. Cai X, Campbell N, Khan B, Callahan C, Boustani M. Chronic anticholinergic use and the aging brain. Alzheimers Dement. 2013;9:377–85.

    Article  PubMed Central  PubMed  Google Scholar 

  39. Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168:508–13.

    Article  PubMed  Google Scholar 

  40. Fox C, Richardson K, Maidment ID, et al. Anticholinergic medication use and cognitive impairment in the older population: the Medical Research Council Cognitive Function and Ageing Study. J Am Geriatr Soc. 2011;59:1477–83.

    Article  PubMed  Google Scholar 

  41. Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU Guideline. American Urological Association; 2014.

  42. Frolich G, Bulitta M, Strosser W. Trospium chloride in patients with detrusor overactivity: meta-analysis of placebo-controlled, randomized, double-blind, multi-center clinical trials on the efficacy and safety of 20 mg trospium chloride twice daily. Int J Clin Pharmacol Ther. 2002;40:295–303.

    Article  Google Scholar 

  43. Zinner N, Gittelman M, Harris R, et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol. 2004;171:2311–5.

    Article  CAS  PubMed  Google Scholar 

  44. Rudy D, Cline K, Harris R, et al. Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology. 2006;67:275–80.

    Article  PubMed  Google Scholar 

  45. Halaska M, Ralph G, Wiedemann A, et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol. 2003;20:392–9.

    CAS  PubMed  Google Scholar 

  46. Staskin DR, Harnett MD. Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder. Curr Sci. 2004;5:423–6.

    Google Scholar 

  47. Diefenbach K, Arnold G, Wollny A, et al. Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged > or = 50 years. BJU Int. 2005;95:346–9.

    Article  CAS  PubMed  Google Scholar 

  48. Silver N, Sandage B, Sabounjian L, et al. Pharmacokinetics of once-daily trospium chloride 60 mg extended release and twice-daily trospium chloride 20 mg in healthy adults. J Clin Pharmacol. 2010;50:143–50.

    Article  CAS  PubMed  Google Scholar 

  49. Staskin DR, Rosenberg MT, Sand PK, et al. Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials. Int J Clin Pract. 2009;63:1715–23.

    Article  CAS  PubMed  Google Scholar 

  50. Zinner NR, Dmochowski RR, Staskin DR, et al. Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms. Neurourol Urodyn. 2011;30:1214–9.

    CAS  PubMed  Google Scholar 

  51. Sand PK, Johnson Ii TM, Rovner ES, et al. Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged ≥75 years) with overactive bladder syndrome. BJU Int. 2011;107:612–20.

    Article  PubMed  Google Scholar 

  52. Sanctura XR™ capsules [package insert]. East Brunswick, NJ: Esprit Pharmaceuticals., and Lexington, MA: Indevus Pharmaceuticals, Inc.; 2008.

  53. Staskin D, Kay G, Tannenbaum C, et al. Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract. 2010;64:1294–300.

    Article  CAS  PubMed  Google Scholar 

  54. Sand PK, Rovner ES, Watanabe JH, Oefelein MG. Once-daily trospium chloride 60 mg extended release in subjects with overactive bladder syndrome who use multiple concomitant medications: post hoc analysis of pooled data from two randomized, placebo-controlled trials. Drugs Aging. 2011;28:151–60.

    Article  CAS  PubMed  Google Scholar 

  55. Chapple C. New once-daily formulation for trospium in overactive bladder. Int J Clin Pract. 2010;64:1535–40.

    Article  CAS  PubMed  Google Scholar 

  56. Douchamps J, Derenne F, Stockis A, et al. The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol. 1998;35:515–20.

    Article  Google Scholar 

  57. Ditropan package insert (Marion Merrell Dow—U.S.); 1992.

  58. Buser N, Ivic S, Kesser TM, et al. Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses. Eur Urol. 2012;62:1040–60.

    Article  CAS  PubMed  Google Scholar 

  59. Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54:543–62.

    Article  CAS  PubMed  Google Scholar 

  60. Ouslander JG, Blaustein J, Connor A, et al. Pharmacokinetics and clinical effects of oxybutynin in geriatric patients. J Urol. 1988;140:47–50.

    CAS  PubMed  Google Scholar 

  61. Szonyi G, Collas DM, Ding YY, et al. Oxybutynin with bladder retraining for detrusor instability in elderly people: a randomized controlled trial. Age Ageing. 1995;24:287–91.

    Article  CAS  PubMed  Google Scholar 

  62. Goode PS, Burgio KL, Locher JL, et al. Urodynamic changes associated with behavioral and drug treatment of urge incontinence in older women. J Am Geriatr Soc. 2002;50:808–16.

    Article  PubMed  Google Scholar 

  63. Kennelly MJ. Oxybutynin chloride formulations: pharmacokinetics and therapeutic efficacy in overactive bladder. Rev Urol. 2010;12:12–9.

    PubMed Central  PubMed  Google Scholar 

  64. Katz IR, Sands LP, Bilker W, et al. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc. 1998;46:8–13.

    Article  CAS  PubMed  Google Scholar 

  65. NICE: National Institute for Health and Care Excellence. Pathway for women with overactive bladder. http://pathways.nice.org.uk/pathways/urinary-incontinence-in-women#path=view%3A/pathways/urinary-incontinence-in-women/overactive-bladder.xml&content=view-index. Accessed 11 Sept 2015.

  66. Ditropan XL package insert (Ortho-McNeil Pharmaceutical, Inc.); 1999.

  67. Birns J, Lukkari E, Malone-Lee JG. A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutynin. BJU Int. 2000;85:793–8.

    Article  CAS  PubMed  Google Scholar 

  68. Novara G, Galfano A, Secco S, et al. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol. 2008;54:740–64.

    Article  CAS  PubMed  Google Scholar 

  69. Siddiqui MA, Perry CM, Scott LJ. Oxybutynin extended-release: a review of its use in the management of overactive bladder. Drugs. 2004;64:885–912.

    Article  CAS  PubMed  Google Scholar 

  70. Aaron LE, Morris TJ, Jahshan P, Reiz JL. An evaluation of patient and physician satisfaction with controlled-release oxybutynin 15 mg as a one-step daily dose in elderly and non-elderly patients with overactive bladder: results of the STOP study. Curr Med Res Opin. 2012;28:1369–79.

    Article  CAS  PubMed  Google Scholar 

  71. Kay G, Crook T, Rekeda L, et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol. 2006;50:317–26.

    Article  CAS  PubMed  Google Scholar 

  72. Nitti VW, Sanders S, Staskin DR, et al. Transdermal delivery of drugs for urologic applications: basic principles and applications. Urology. 2006;67:657–64.

    Article  PubMed  Google Scholar 

  73. Oxytrol [package insert]. Corona, California, Watson Pharma, Incorporated; 2003.

  74. Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Adult Urol. 2003;62:237–42.

    Article  PubMed  Google Scholar 

  75. Sand P, Zinner N, Newman D, et al. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicenter, community-based, randomized study. BJU Int. 2007;99:836–44.

    Article  CAS  PubMed  Google Scholar 

  76. Watson Pharmaceuticals, Inc. Gelnique® prescribing information. 2008.

  77. Staskin DR, Robinson D. Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder. Expert Opin Pharmacother. 2009;10:3103–11.

    Article  CAS  PubMed  Google Scholar 

  78. Sand PK, Davila GW, Lucente VR, et al. Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome. Am J Obstet Gynecol. 2012;206:168.e1–6.

  79. Kay GG, Staskin DR, MacDiarmid S, et al. Cognitive effects of oxybutynin chloride topical gel in older healthy subjects: a 1-week, randomized, double-blind, placebo- and active-controlled study. Clin Drug Investig. 2012;32:707–14.

    Article  CAS  PubMed  Google Scholar 

  80. Nilvebrant L, Hallen B, Larssen G. Tolterodine – a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Life Sci. 1997;60:1129–36.

    Article  CAS  PubMed  Google Scholar 

  81. Michel MC. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother. 2008;9:1787–96.

    Article  CAS  PubMed  Google Scholar 

  82. Chapple C, Van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol. 2007;52:1204–12.

    Article  CAS  PubMed  Google Scholar 

  83. Nitti VW, Dmochowski RR, Sand PK, et al. Efficacy, safety, and tolerability of fesoterodine for overactive bladder syndrome. J Urol. 2007;178:2488–94.

    Article  CAS  PubMed  Google Scholar 

  84. Wagg A, Khullar V, Marschall-Kehrel D, et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population. J Am Geriatr Soc. 2013;61:185–93.

    Article  PubMed  Google Scholar 

  85. Wagg A, Khullar V, Michel MC, Oelke M, Darekar A, Bitoun CE. Long-term safety, tolerability and efficacy of flexible-dose fesoterodine in elderly patients with overactive bladder: open-label extension of the SOFIA trial. Neurourol Urodynam. 2014;33:106–14.

    Article  CAS  Google Scholar 

  86. DuBeau CE, Kraus SR, Griebling TL, et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled Trial. J Urol. 2014;191:395–404.

    Article  CAS  PubMed  Google Scholar 

  87. Natalin R, Lorenzetti F, Dambros M. Management of OAB in those over age 65. Curr Urol Rep. 2013;14:379–85.

    Article  PubMed  Google Scholar 

  88. Chughtai B, Levin R, De E. Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin. Clin Interv Aging. 2008;3:503–9.

    PubMed Central  CAS  PubMed  Google Scholar 

  89. Chapple C, Steers W, Norton P, et al. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int. 2004;95:993–1001.

    Article  Google Scholar 

  90. Chapple C, DuBeau C, Ebinger U, et al. Darifenacin treatment of patients ≥65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Curr Med Res Opin. 2007;23:2347–58.

    Article  CAS  PubMed  Google Scholar 

  91. Kay GG, Ebinger U. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract. 2008;62:1792–800.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  92. Kay GG, Wesnes K. Pharmacodynamic effects of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of over- active bladder, in healthy volunteers. BJU Int. 2005;96:1055–62.

    Article  CAS  PubMed  Google Scholar 

  93. Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol. 2005;173:493–8.

    Article  PubMed  Google Scholar 

  94. Tack J, Wyndaele JJ, Ligozio G, Egermark M. A review and additional post-hoc analyses of the incidence and impact of constipation observed in darifenacin clinical trials. Drug Healthc Patient Saf. 2012;4:127–39.

    Article  PubMed Central  PubMed  Google Scholar 

  95. Olshanky B, Ebinger U, Brum J, et al. Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants > or = 50 years. J Cardiovasc Pharmacol Ther. 2008;13:241–51.

    Article  Google Scholar 

  96. Hill S, Elhilali M, Millard RJ, et al. Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study. Curr Med Res Opin. 2007;23:2697–704.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, LSU Health Sciences Center-Shreveport, 1501 Kings Highway, Shreveport, LA, 71130, USA

    Scott C. McFerren & Alex Gomelsky

Authors
  1. Scott C. McFerren
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alex Gomelsky
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alex Gomelsky.

Ethics declarations

Conflict of interest

S. Clint McFerren and Alex Gomelsky declare that they have no conflict of interest.

Funding

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McFerren, S.C., Gomelsky, A. Treatment of Overactive Bladder in the Elderly Female: The Case for Trospium, Oxybutynin, Fesoterodine and Darifenacin. Drugs Aging 32, 809–819 (2015). https://doi.org/10.1007/s40266-015-0301-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-015-0301-x

Keywords

Search

Navigation